Hepatitis B virus (HBV) infection is a major public health burden in China, and chronically infected HBV patients are at a high risk of developing hepatic cirrhosis and hepatocellular carcinoma. The majority of hepatitis B virus patients in China are prescribed older, generic agents such as pegylated interferon-α-2a (Pegasys), pegylated interferon-α-2b (Peg-Intron), tenofovir disoproxil fumarate (Viread), and entecavir (Baraclude). However, we expect the recently launched tenofovir alafenamide (Gilead’s Vemlidy), in addition to several novel therapies set to launch for hepatitis B virus during the forecast period, to result in significant growth of the Chinese hepatitis B virus market. Moreover, we expect ongoing reforms in China’s regulatory and A&R landscape to encourage MNCs to enter the hepatitis B virus market.
- How large is China’s drug-treatable hepatitis B virus population, and how will the drug-treatment rate change during the forecast period?
- Which are the most commercially relevant drugs in China’s hepatitis B virus market and why? What are interviewed experts’ insights into current treatment options? Which clinical needs remain unfulfilled?
- What are the key market access considerations for key therapies in the hepatitis B virus pipeline in China? What is their potential in terms of sales/uptake in hepatitis B virus? What are interviewed experts’ opinions on the key emerging therapies?
- What are the key drivers and constraints in the Chinese hepatitis B virus market, and how will the market evolve over the forecast period?
China In-Depth offers comprehensive market intelligence, including world-class epidemiology, keen insight into the China-specific A&R environment, current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research. This solution helps companies gauge commercial outlooks and optimize clinical development, subpopulation targeting, physician messaging, and overall long-term strategy in China.
Country-specific qualitative and quantitative insights driven by 5 thought-leader interviews and 50 surveys with hepatologists and gastroenterologists. Supported by survey data collected for this and other DRG research.
Total prevalence of hepatitis B virus in urban versus rural China; clinically relevant and market-relevant drug-treatable populations.
10-year, annualized, drug-level sales and patient shares of key hepatitis B virus agents through 2029, based on primary and secondary market research to formulate bottom-up assumptions
Phase III/PR: 4 drugs; Phase II: 10 drugs; coverage of select preclinical and Phase I products
- Hepatitis B Virus - Geographic Focus: China - Hepatitis B Virus - China In-Depth - China
- China In-Depth Hepatitis B Virus
Author(s): Karan Verma, MSc; Alison Isherwood, MSc, MRes, PhD
Karan is a Senior Analyst with the China-in-Depth team at Decision Resources Group, where he specializes in disease landscape and forecast reports based on a range of indications and therapy areas and focused specifically on the China healthcare market.
Before joining DRG, Karan was associated with Aranca, a boutique management consulting firm. Prior to that, he was working with Frost & Sullivan, a global healthcare consulting firm, where he was helping clients devise market entry strategies, conducting technology feasibility studies, and doing competitive intelligence for new product development. His prior experience also includes a short KTP program with the University of Southampton, UK. Karan has earned his MSc in Biomedical Engineering from the University of Warwick, and B.E. in Biomedical Engineering from Maharshi Dayanand University, Haryana, India.
Alison Isherwood, B.Sc., M.Res., M.Sc., Ph.D. joined Decision Resources Group in 2008, as an Epidemiologist. Alison holds a B.Sc. in Medical Microbiology, Masters by Research in the Life Sciences and a M.Sc. in Epidemiology all from the University of Edinburgh. Prior to joining Decision Resources Inc., she was working on her Ph.D. in Molecular Virology, specializing on the severe acute respiratory syndrome (SARS) coronavirus, at the University of Reading. In her role at Decision Resources Group, Alison is currently an Epidemiology team lead as well as project managing custom epidemiology work in multiple therapy areas. Alison’s area of specialization at DRG is cancer, particularly breast cancer.